Highlights Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 00:00:02 07/03/2026 +03			5-day change	1st Jan Change
115.79 ^USD	-0.24%		-6.49%	+10.00%

03-06	Top pharma companies racing to launch a weight-loss pill	RE
03-04	Health Rounds: Laser treatment before immunotherapy helps brain cancer patients live longer	RE

Highlights

03-03	Tempus AI, Merck Collaborate on AI-Driven Precision Medicine	MT
03-02	United Therapeutics' drug slows progression of rare lung condition in late-stage study	RE
02-28	Merck Announces the Presentation of Results from the Pivotal Phase 3 Litespark-022 Trial Evaluating Keytruda	CI
02-28	Merck Announces the Presentation of Results from the Pivotal Phase 3 Litespark-022 Trial Evaluating Keytruda	CI
02-28	Sector Update: Health Care Stocks Advance Late Afternoon	MT
02-27	Merck & Co., Inc. Announces Results Of Phase 3 KEYNOTE-B96 Trial For KEYTRUDA Plus Paclitaxel With Or Without Bevacizumab In Platinum-Resistant Recurrent Ovarian Cancer	CI
02-27	Merck & Co., Inc. Announces KEYTRUDA®? (Pembrolizumab) Plus Padcev®? (enfortumab Vedotin-Ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Ejfv	CI
02-26	Synthekine Inc. Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 in Combination with Keytruda (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer	CI
02-26	FDA clears Merck's Numelvi, first second-gen JAK inhibitor for canine pruritus	RE
02-25	Merck & Co., Inc. Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL) an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026	CI
02-24	Sector Update: Health Care Stocks Higher Late Afternoon	MT
02-23	Global markets live: Nvidia, Gilead, Goldman Sachs, Delta Air Lines, Novo Nordisk…
02-23	New Rules
02-23	Gossamer Bio shares plummet as lung disease drug fails late-stage trial	RE
02-19	Merck Announces Positive New Data for ENFLONSIA (Caresrovimab) for Infants and Children Under 2 Years of Age At Increased Risk for Severe Respiratory Syncytial Virus Disease over Two RSV Seasons	CI
02-18	Merck to Collaborate With Mayo Clinic on AI-Enabled Drug Discovery	MT
02-17	Health Canada approves Keytruda SC(TM), a subcutaneous formulation of pembrolizumab across multiple cancer indications	RE
02-17	Merck Says Health Canada Approves Keytruda SC for Multiple Cancer Indications	MT
02-17	Merck announces Health Canada Approves KEYTRUDA SC?, a Subcutaneous Formulation of Pembrolizumab Across Multiple Cancer Indications	CI
02-13	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid January Consumer Price Inflation Report	MT
02-12	Merck Advances Treatment of Bladder and Kidney Cancers with New Data At 2026 ASCO GU Cancers Symposium	CI
02-11	Merck Announces the U.S. Food and Drug Administration Approves KEYTRUDA (Pembrolizumab and Berahyaluronidase Alfa-Pmph) and KEYTRUDA QLEX	CI
02-11	Merck Says US FDA Approves Keytruda Combination in Platinum-Resistant Ovarian Cancer	MT
02-11	FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, primary peritoneal carcinoma	RE
02-10	Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform	CI